U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-QSB
(Mark One)
|X| Quarterly report pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
For the quarterly period ended September 30, 2001
|_| Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
for the transition period from __________ to ____________.
Commission file number 0-27282
ATLANTIC TECHNOLOGY VENTURES, INC.
-----------------------------------------------------------------
(Exact name of small business issuer as specified in its charter)
Delaware 36-3898269
------------------------------- -------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
350 Fifth Avenue, Suite 5507, New York, New York 10118
------------------------------------------------------
(Address of principal executive offices)
(212) 267-2503
---------------------------
(Issuer's telephone number)
150 Broadway, Suite 1110, New York, New York 10038
---------------------------------------------------------------
(Former name, former address and former fiscal year, if changed
since last report)
Check whether the issuer: (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes |X| No |_|
Number of shares of common stock outstanding as of November 14, 2001: 7,201,480
Transitional Small Business Disclosure Format (check one): Yes |_| No |X|
INDEX
Page
PART I -- FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements
Consolidated Balance Sheets (unaudited)
as of September 30, 2001 and December 31, 2000 3
Consolidated Statements of Operations (unaudited) for
the three and nine months ended September 30, 2001
and 2000, and the period from July 13, 1993
(inception) to September 30, 2001 4
Consolidated Statements of Cash Flows (unaudited) for
the nine months ended September 30, 2001 and 2000,
and the period from July 13, 1993 (inception) to
September 30, 2001 5
Notes to Consolidated Financial Statements (unaudited) 6
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations 11
PART II-- OTHER INFORMATION
Item 2. Changes in Securities
Item 4. Submission of Matters to a Vote of Security Holders 17
Item 5. Other Information 17
Item 6. Exhibits and Reports on Form 8-K 17
SIGNATURES 23
2
PART I -- FINANCIAL INFORMATION
Item 1. Financial Statements
ATLANTIC TECHNOLOGY VENTURES, INC. AND SUBSIDIARIES
(A Development Stage Company)
Consolidated Balance Sheets
(Unaudited)
September 30, December 31,
Assets 2001 2000
---------------------------------------------------------------------------- ------------ ------------
Current assets:
Cash and cash equivalents $ 440,558 2,663,583
Accounts receivable -- 192,997
Prepaid expenses 27,194 22,599
------------ ------------
Total current assets 467,752 2,879,179
Property and equipment, net 116,364 227,088
Investment in affiliate 8,351 67,344
Other assets 22,838 2,901
------------ ------------
Total assets $ 615,305 3,176,512
============ ============
Liabilities and Stockholders' Equity (Deficit)
Current liabilities:
Accounts payable and accrued expenses $ 748,359 785,838
Deferred revenue -- 1,294,615
------------ ------------
Total current liabilities $ 748,359 2,080,453
Redeemable Series B convertible preferred stock
Authorized 1,647,312 shares; 0 and 206,898 shares issued and
outstanding at September 30, 2001 and December 31, 2000 respectively -- 600,000
Stockholders' equity (deficit):
Preferred stock, $.001 par value. Authorized 10,000,000
shares; 1,375,000 shares designated as Series A
convertible preferred stock -- --
Series A convertible preferred stock, $.001 par value
Authorized 1,375,000 shares; 350,606 and 359,711 shares issued and
outstanding at September 30, 2001 and December 31, 2000, respectively
(liquidation preference aggregating $4,557,878 and $4,676,243 at
September 30, 2001
and December 31, 2000, respectively) 351 360
Convertible preferred stock warrants, 112,896
issued and outstanding at September 30, 2001 and
December 31, 2000 520,263 520,263
Common stock, $.001 par value. Authorized 50,000,000
shares; 7,201,480 and 6,122,135 shares issued and outstanding
at September 30, 2001 and December 31, 2000, respectively 7,201 6,122
Common stock subscribed. 182 shares at September 30, 2001
and December, 31, 2000 -- --
Additional paid-in capital 25,502,927 24,796,190
Deficit accumulated during development stage (26,163,254) (24,826,334)
------------ ------------
(132,512) 496,601
Less common stock subscriptions receivable (218) (218)
Less treasury stock, at cost (324) (324)
------------ ------------
Total stockholders' equity (deficit) (133,054) 496,059
------------ ------------
Total liabilities and stockholders' equity (deficit) $ 615,305 3,176,512
============ ============
See accompanying notes to unaudited consolidated financial statements.
3
ATLANTIC TECHNOLOGY VENTURES, INC. AND SUBSIDIARIES
(A Development Stage Company)
Consolidated Statements of Operations
(Unaudited)
Cumulative
period from
July 13, 1993
Three months ended Nine months ended (inception) to
September 30, September 30, September 30,
-------------------------- -------------------------- -------------
2001 2000 2001 2000 2001
----------- ----------- ----------- ----------- -----------
Revenues:
Development revenue $ -- $ 1,072,716 $ 2,461,922 $ 3,419,831 $ 8,713,720
License revenue -- -- -- -- 2,500,000
Grant revenue -- -- 250,000 13,009 616,659
----------- ----------- ----------- ----------- -----------
Total revenues -- 1,072,716 2,711,922 3,432,840 11,830,379
----------- ----------- ----------- ----------- -----------
Costs and expenses:
Cost of development revenue -- 858,173 2,082,568 2,735,865 7,084,006
Research and development 172,257 424,829 774,340 854,297 10,279,250
Acquired in-process research and development -- 263,359 -- 2,653,382 2,653,382
General and administrative 496,294 477,949 2,333,567 1,595,463 18,236,793
Compensation expense relating to stock warrants, net
(general and administrative) 35,968 11,857 70,634 1,073,511 1,091,499
License fees -- -- -- -- 173,500
----------- ----------- ----------- ----------- -----------
Total operating expenses 704,519 2,036,167 5,261,109 8,912,518 39,518,430
----------- ----------- ----------- ----------- -----------
Operating loss (704,519) (963,451) (2,549,187) (5,479,678) (27,688,051)
Other (income) expense:
Interest and other income (6,266) (22,940) (40,618) (97,267) (1,291,754)
Gain on sale of Optex assets -- -- (2,569,451) -- (2,569,451)
Loss on sale of Gemini assets -- -- 334,408 -- 334,408
Interest expense -- -- -- -- 625,575
Equity in (earnings) loss of affiliate 37,309 31,915 58,993 55,615 138,267
Distribution to minority shareholders -- -- 837,274 -- 837,274
----------- ----------- ----------- ----------- -----------
Total other (income) expense 31,043 8,975 (1,379,394) (41,652) (1,925,681)
----------- ----------- ----------- ----------- -----------
Net loss $ (735,562) $ (972,426) $(1,169,793) $(5,438,026) $(25,762,370)
=========== =========== =========== =========== ============
Imputed convertible preferred stock dividend -- -- 600,000 -- 5,931,555
Dividend paid upon repurchase of Series B -- -- 167,127 -- 400,884
Preferred stock dividend issued in preferred shares 43,305 152,195 107,449 811,514 1,390,512
----------- ----------- ----------- ----------- -----------
Net loss applicable to common shares $ (778,867) $(1,124,621) $(2,044,369) $(6,249,540) $(33,485,321)
=========== =========== =========== =========== ============
Net loss per common share:
Basic and diluted $ (0.11) $ (0.19) $ (0.30) $ (1.14)
=========== =========== =========== ===========
Weighted average shares of common stock outstanding,
basic and diluted: 7,166,090 6,033,257 6,734,788 5,504,144
=========== =========== =========== ===========
See accompanying notes to unaudited consolidated financial statements.
4
ATLANTIC TECHNOLOGY VENTURES, INC. AND SUBSIDIARIES
(A Development Stage Company)
Consolidated Statements of Cash Flows
(Unaudited)
Cumulative
period from
Nine months ended July 13, 1993
September 30, (inception) to
---------------------------- September 30,
2001 2000 2001
----------- ----------- -------------
Cash flows from operating activities:
Net loss (1,169,793) (5,438,026) (25,762,370)
Adjustments to reconcile net loss to
net cash used in operating activities:
Acquired in-process research and development -- 1,800,000 1,800,000
Expense relating to issuance of common stock and warrants 488,100 -- 786,302
Expense relating to the issuance of options -- -- 81,952
Expense related to Channel merger -- -- 657,900
Change in equity of affiliate 58,993 55,615 138,267
Compensation expense relating to stock options and warrants 70,634 1,073,511 1,299,544
Discount on notes payable - bridge financing -- -- 300,000
Depreciation 55,015 51,529 561,520
Gain on sale of Optex assets (2,569,451) -- (2,569,451)
Distribution to Optex minority shareholders 837,274 -- 837,274
Loss on sale of Gemini assets 334,408 -- 334,408
Loss on disposal of furniture and equipment -- -- 73,387
Changes in assets and liabilities:
(Increase) decrease in accounts receivable 192,997 (700,188) --
Increase in prepaid expenses (4,595) (20,185) (27,194)
Decrease in deferred revenue (1,294,615) -- --
Increase (decrease) in accrued expenses (664,637) 519,025 121,201
Increase (decrease) in accrued interest -- -- 172,305
Increase in other assets (19,937) (2,901) (22,838)
----------- ----------- -----------
Net cash used in operating activities (3,685,607) (2,661,620) (21,217,793)
----------- ----------- -----------
Cash flows from investing activities:
Purchase of furniture and equipment (108,250) (137,869) (921,331)
Investment in affiliate -- (146,618) (146,618)
Proceeds from sale of Optex assets 3,000,000 -- 3,000,000
Proceeds from sale of furniture and equipment -- -- 6,100
----------- ----------- -----------
Net cash provided by (used in) investing activities 2,891,750 (284,487) 1,938,151
----------- ----------- -----------
Cash flows from financing activities:
Proceeds from exercise of warrants -- -- 5,500
Proceeds from exercise of stock options -- 344,597 397,098
Proceeds from issuance of demand notes payable -- -- 2,395,000
Repayment of demand notes payable -- -- (125,000)
Proceeds from the issuance of notes payable - bridge financing -- -- 1,200,000
Proceeds from issuance of warrants -- -- 300,000
Repayment of notes payable - bridge financing -- -- (1,500,000)
Repurchase of common stock -- -- (324)
Preferred stock dividend paid (987) -- (1,305)
Proceeds from the issuance of common stock -- -- 7,547,548
Proceeds from issuance of convertible preferred stock -- 828,489 11,441,672
Repurchase of convertible preferred stock (617,067) -- (1,128,875)
Distribution to Optex minority shareholders (811,114) -- (811,114)
----------- ----------- -----------
Net cash provided (used in) by financing activities (1,429,168) 1,173,086 19,720,200
----------- ----------- -----------
Net decrease in cash and cash equivalents (2,223,025) (1,773,021) 440,558
Cash and cash equivalents at beginning of period 2,663,583 3,473,321 --
----------- ----------- -----------
Cash and cash equivalents at end of period 440,558 1,700,300 440,558
=========== =========== ===========
Supplemental disclosure of noncash financing activities:
Issuance of common stock in exchange for common stock subscriptions -- -- 7,027
Conversion of demand notes payable and the related accrued
interest to common stock -- -- 2,442,304
Cashless exercise of preferred warrants -- 19,811 49,880
Conversion of preferred to common stock 409 289 2,835
Preferred stock dividend issued in shares 107,449 811,514 1,233,329
=========== =========== ===========
See accompanying notes to unaudited consolidated financial statements.
5
ATLANTIC TECHNOLOGY VENTURES, INC. and SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
September 30, 2001
(1) BASIS OF PRESENTATION
The accompanying consolidated financial statements have been
prepared in accordance with accounting principles generally accepted in the
United States of America for interim financial information. Accordingly, the
financial statements do not include all information and footnotes required by
accounting principles generally accepted in the United States of America for
complete annual financial statements. In the opinion of management, the
accompanying financial statements reflect all adjustments, consisting of only
normal recurring adjustments, considered necessary for fair presentation.
Interim operating results are not necessarily indicative of results that may be
expected for the year ending December 31, 2001 or for any subsequent period.
These consolidated financial statements should be read in conjunction with
Atlantic Technology Ventures, Inc., and Subsidiaries' ("Atlantic") Annual Report
on Form 10-KSB/A as of and for the year ended December 31, 2000.
(2) LIQUIDITY
On November 6, 2001, Atlantic entered into an agreement with Joseph
Stevens & Company, Inc. in which Joseph Stevens agreed to act as placement agent
for a private placement of shares of Atlantic common stock. In that private
placement, the proposed purchase price of each share of Atlantic common stock
will be $0.24 and the minimum and maximum aggregate subscription amounts will be
$2,000,000 and $3,000,000, respectively. In addition, each investor will receive
a warrant to purchase one share of Atlantic common stock for every share of
Atlantic common stock purchased by that investor. The warrants will have an
exercise price of $0.29 and will be exercisable for five years from the closing
date. In connection with the offering, Atlantic will pay to Joseph Stevens a
placement fee equal to 7% of the aggregate subscription amount plus 10% of the
number of shares and warrants issued to the investors. Joseph Stevens has
informed Atlantic that as of the end of November 19, 2001, investors had placed
in escrow over $1,000,000 towards the aggregate subscription price of this
private placement, and Atlantic expects that by November 30, 2001, it will have
received commitments for at least the minimum aggregate subscription amount and
will be able to close this financing. There can, however, be no assurances that
the closing will take place by then, or at all.
Atlantic anticipates that their liquid resources, before any
proceeds from the proposed private placement, will be sufficient to finance
their anticipated needs for operating and capital expenditures at their current
level of operations for at least the next several weeks. Atlantic will attempt
to generate additional capital through a combination of collaborative
agreements, strategic alliances and equity and debt financing, and Atlantic
anticipates that the proceeds it expects to receive from the private placement
conducted through Joseph Stevens & Company, Inc. would be sufficient to finance
its anticipated needs for operating and capital expenditures at their current
level of operations for at least the next year. However, Atlantic can give no
assurance that they will receive any proceeds from the proposed private
placement or obtain funds through other sources on terms acceptable to them.
On May 7, 2001, Atlantic entered into a common stock purchase
agreement with Fusion Capital Fund II, LLC pursuant to which Fusion Capital
agreed to purchase up to $6.0 million of our common stock. This agreement
replaced an earlier common stock purchase agreement between Atlantic and Fusion
Capital dated March 16, 2001. Fusion's obligation to purchase Atlantic shares is
subject to certain conditions, including the effectiveness of a registration
statement covering the shares to be purchased. That registration statement was
declared effective on July 6, 2001. A material contingency that may affect
Atlantic's operating plans and ability to raise funds under this agreement is
its stock price. Currently, Atlantic's stock price is below the floor price of
$0.68 specified in the Fusion Capital agreement and as a result Atlantic is
currently unable to draw funds pursuant to the Fusion Capital agreement. As the
Fusion Capital agreement is currently structured, Atlantic cannot guarantee that
it will be able to draw any funds. To date, Atlantic has not drawn funds
pursuant to this agreement. See note 11 below and see the liquidity discussion
within "Management's Discussion and Analysis of Financial Condition and Results
of Operations."
Subsequent to an oral hearing before a Nasdaq Listing Qualifications
Panel, on August 23, 2001, Atlantic's securities were delisted from the Nasdaq
Stock Market for failing to meet the minimum bid price requirements set forth in
the NASD Marketplace Rules, as Atlantic's common stock had traded for less than
$1.00 for more than 30
6
consecutive business days. Atlantic's common stock now trades on the OTC
Bulletin Board under the symbol "ATLC.OB". Delisting of Atlantic's common stock
from Nasdaq could have a material adverse effect on its ability to raise
additional capital, its stockholders' liquidity and the price of its common
stock.
(3) COMPUTATION OF NET LOSS PER COMMON SHARE
Basic net loss per common share is calculated by dividing net loss
applicable to common shares by the weighted-average number of common shares
outstanding for the period. Diluted net loss per common share is the same as
basic net loss per common share, as common equivalent shares from stock options,
stock warrants, stock subscriptions, and convertible preferred stock would have
an antidilutive effect because Atlantic incurred a net loss during each period
presented.
(4) RECENTLY ISSUED ACCOUNTING STANDARDS
On January 1, 2001, Atlantic adopted the provisions of Statement of
Financial Accounting Standards (SFAS) No. 138, "Accounting for Certain
Derivative Instruments and Certain Hedging Activities--an amendment of SFAS No.
133" and SFAS No. 133, "Accounting for Certain Derivative Instruments and
Certain Hedging Activities." SFAS No. 138 amends the accounting and reporting
standards of SFAS No. 133 for certain derivative instruments and certain hedging
activities. SFAS No. 133 requires a company to recognize all derivative
instruments as assets and liabilities in its balance sheet and measure them at
fair value. The adoption of these statements did not have a material impact on
Atlantic's consolidated financial position, results of operations or cash flows,
as Atlantic is currently not party to any derivative instruments.
In July 2001, the FASB issued SFAS No. 141, "Business Combinations,"
and SFAS No. 142, "Goodwill and Other Intangible Assets." SFAS No. 141 requires
that all business combinations be accounted for under a single method--the
purchase method. Use of the pooling-of-interests method is no longer permitted.
SFAS No. 141 requires that the purchase method be used for business combinations
initiated after June 30, 2001. SFAS No. 142 requires that goodwill no longer be
amortized to earnings, but instead be reviewed for impairment. The amortization
of goodwill ceases upon adoption of the Statement, which for calendar year-end
companies, will be January 1, 2002. SFAS No. 142 has no financial impact on
Atlantic since Atlantic does not have any goodwill or intangible assets which
resulted from any previous business combinations.
(5) INCOME TAXES
Atlantic incurred a net loss for the three and nine months ended
September 30, 2001. In addition, Atlantic does not expect to generated book
income for the year ended December 31, 2001; therefore, no income taxes have
been reflected for the three and nine months ended September 30, 2001.
(6) PREFERRED STOCK DIVIDEND
On January 16, 2001 and August 7, 2001, Atlantic's board of
directors declared payment-in-kind dividends of 0.065 of a share of Series A
convertible preferred stock for each share of Series A convertible preferred
stock held as of the record dates of February 7, 2001 and August 7, 2001
respectively. The estimated fair value of these dividends in the aggregate of
$43,305 and $107,449 were included in Atlantic's calculation of net loss per
common share for the three-and nine-month periods ended September 30, 2001,
respectively. The equivalent dividends for the three-and nine-month periods
ended September 30, 2000 had an estimated fair value of $152,195 and $811,514,
respectively and are recorded in the same manner.
(7) ISSUANCE OF STOCK WARRANTS
As more fully described in Note 9 to Atlantic's Annual Report on
Form 10-KSB/A as of and for the year ended December 31, 2000, on January 4,
2000, Atlantic entered into a financial advisory and consulting agreement with
Joseph Stevens & Company, Inc. pursuant to which Atlantic issued to Joseph
Stevens & Company, Inc. three warrants to purchase an aggregate of 450,000
shares of its common stock. Atlantic recorded compensation expense relating to
these stock warrants in the amounts of $11,857 and $1,073,511 for the three-and
nine-month periods
7
ended September 30, 2000, respectively. No such compensation expense exists
subsequent to December 31, 2000 as the warrants are fully vested. These warrants
were still outstanding as of September 30, 2001.
On March 8, 2001, Atlantic entered into an agreement with The
Investor Relations Group, Inc. ("IRG") under which IRG will provide Atlantic
investor relations services. Pursuant to this agreement, Atlantic issued to Dian
Griesel, the principal of IRG, warrants to purchase 120,000 shares of its common
stock at an exercise price of $0.875 per share. These warrants will vest monthly
in 5,000 share increments over a 24-month period. In addition, should Atlantic's
stock price reach $2.50, Atlantic will grant Dian Griesel warrants to purchase
an additional 50,000 shares of its common stock, and should Atlantic's stock
price reach $5.00, Atlantic will grant Dian Griesel warrants to purchase a
further 50,000 shares of its common stock. As a result, Atlantic recorded
compensation expense relating to the issuance of the stock warrants to purchase
120,000 shares of $38,200 for the nine-month period ended September 30, 2001
pursuant to EITF Issue No. 96-18. As a result of a decline in Atlantic's common
stock price during the three months ended September 30, 2001, the cumulative
expense associated with these warrants was reduced. The depreciation in the
estimated fair value of the warrants previously recorded and the current quarter
expense resulted in a net reversal of compensation expense of $9,387 which is
recorded during the three months ended September 30, 2001. Atlantic will
remeasure the compensation expense at the end of each reporting period until the
final measurement date is reached 24 months after issuance. These warrants are
outstanding as of September 30, 2001.
On August 9, 2001, Atlantic entered into an agreement with Proteus
Capital Corp. ("Proteus") in which Proteus agreed to assist Atlantic with
raising additional funds. Pursuant to this agreement, Atlantic granted Proteus
warrants to purchase 100,000 shares of its common stock at $0.59 per share,
which was the average closing stock price for the two weeks ending August 17,
2001. The warrants were fully vested on the date of the agreement and were
outstanding at September 30, 2001. The term of the warrants is five years.
Atlantic recorded compensation expense relating to these stock warrants of
$45,355 for the three and nine months ended September 30, 2001, pursuant to EITF
Issue No. 96-18.
Compensation for these warrants relates to fundraising and investor
relations services and represents a general and administrative expense.
(8) REDEEMABLE SERIES B PREFERRED SHARES
On September 28, 2000, pursuant to a convertible preferred stock and
warrants purchase agreement (the "Purchase Agreement") Atlantic issued to BH
Capital Investments, L.P. and Excalibur Limited Partnership (together, the
"Investors") for a purchase price of $2,000,000, 689,656 shares of Atlantic's
Series B convertible preferred stock and warrants to purchase 134,000 shares of
Atlantic's common stock. Half of the shares of the Series B preferred stock
(344,828 shares) and warrants to purchase half of the shares of common stock
(67,000 shares) were held in escrow, along with half of the purchase price.
On December 4, 2000, Atlantic and the Investors entered into a stock
repurchase agreement (the "Repurchase Agreement") pursuant to which Atlantic
repurchased from the investors a portion of the outstanding shares.
Pursuant to Atlantic's subsequent renegotiations with the Investors,
Atlantic was required, among other things, to redeem on March 28, 2002, all
outstanding shares of Series B preferred stock for (A) 125% of the original
issue price per share or (B) the market price of the shares of common stock into
which they are convertible, whichever is greater (the "Redemption Price").
Atlantic would have been able to at any time redeem all outstanding shares of
Series B preferred stock at the Redemption Price. As a result of the
renegotiations discussed in this paragraph, the Series B preferred stock was
considered redeemable and the remaining outstanding shares at December 31, 2000
were classified outside of permanent equity in the accompanying consolidated
balance sheet. At December 31, 2000, of the shares of Series B preferred stock
issued to the Investors, there were 206,898 shares outstanding at a carrying
amount of $2.90 per share.
Holders of shares of Atlantic's outstanding Series B preferred stock
could convert each share into shares of common stock without paying Atlantic any
cash. The conversion price per share of the Series B preferred stock was also
amended by the second amendment to the Purchase Agreement. The conversion price
per share of Series B
8
preferred stock on any given day is the lower of (1) $1.00 or (2) 90% of the
average of the two lowest closing bid prices on the principal market of the
common stock out of the fifteen trading days immediately prior to conversion.
The change in conversion price upon the renegotiations on January 9, 2001
resulted in a difference between the conversion price of the Series B preferred
stock and the market price of the common stock on the effective date of the
renegotiation. This amount, estimated at $600,000, was recorded as an imputed
preferred stock dividend within equity and is deducted from net loss to arrive
at net loss applicable to common shares during the nine months ended September
30, 2001.
On January 19, 2001, 41,380 shares of Series B preferred stock were
converted by the Investors into 236,422 shares of Atlantic's common stock. On
March 9, 2001, Atlantic and the Investors entered into a second stock repurchase
agreement pursuant to which Atlantic repurchased from the Investors, for an
aggregate purchase price of $617,067, all 165,518 shares of Atlantic's Series B
preferred stock held by the Investors on March 9, 2001. The carrying amount of
the 165,518 shares is equal to $480,000; therefore the amount in excess of the
carrying amount, which equals $167,127, was recorded as a dividend upon
repurchase of shares of Series B preferred stock and is deducted from net loss
to arrive at net loss applicable to common shares.
(9) DEVELOPMENT REVENUE
In accordance with an amended license and development agreement,
which was subsequently terminated as described below in note 10, Bausch & Lomb
Surgical reimbursed Atlantic's subsidiary, Optex Ophthalmologics, Inc.
("Optex"), for costs Optex incurred in developing its Catarex technology, plus a
profit component. For the nine months ended September 30, 2001, this agreement
provided $2,461,922 of development revenue, and related cost of development
revenue of $2,082,568. This agreement provided $1,072,716 and $3,419,831 of
development revenue, and related cost of development revenue of $858,173 and
$2,735,865 for the three-and nine-month periods ended September 30, 2000
respectively. The agreement was terminated in March 2001 (see note 10 below).
Accordingly, there was no development revenue or related expense for the
three-month period ended September 30, 2001.
(10) SALE OF OPTEX ASSETS
Pursuant to an asset purchase agreement dated January 31, 2001,
among Bausch & Lomb, a Bausch & Lomb affiliate, Atlantic, and Optex, on March 2,
2001, Optex sold to Bausch & Lomb substantially all of its assets (mostly
intangible assets with no book value), including all those related to the
Catarex technology. The purchase price was $3 million paid at closing (of which
approximately $564,000 has been distributed to Optex's minority shareholders).
In addition, Optex is entitled to receive additional consideration, namely $1
million once Bausch & Lomb receives regulatory approval to market the Catarex
device in Japan, royalties on net sales on the terms stated in the original
development agreement dated May 14, 1998, between Bausch & Lomb and Optex, as
amended, and minimum royalties of $90,000, $350,000, and $750,000 for the first,
second, and third years, respectively, starting on first commercial use of the
Catarex device or January 1, 2004, whichever is earlier. Optex also has the
option to repurchase the acquired assets from Bausch & Lomb at fair value if it
ceases developing the Catarex technology.
Upon the sale of Optex assets, Bausch & Lomb's development agreement
with Optex was terminated and Optex has no further involvement with Bausch &
Lomb. As a result of this transaction, Atlantic recorded a net gain on the sale
of Optex assets of $2,569,451 for the nine-month period ended September 30,
2001, net of severance payments to former Optex employees in the amount of
$240,000 as described below. The purchase price of $3,000,000 is nonrefundable
and upon the closing of the asset purchase agreement in March 2001, Optex had no
further obligation to Bausch & Lomb or with regard to the assets sold. In the
asset purchase agreement, Optex agreed to forgo future contingent payments
provided for in the earlier development agreement. Pursuant to Atlantic's
agreement with the minority shareholders of Optex, Optex has recorded a profit
distribution for the nine months ended September 30, 2001 of $837,274
representing the minority shareholders' percentage of the cumulative profit from
the Bausch & Lomb development and asset purchase agreements up to and including
proceeds from the sale of Optex' assets.
On May 9, 2001, Atlantic's board of directors, after consideration
of all the relevant facts and circumstances, including recommendation of
counsel, agreed to authorize an aggregate payment of $240,000 to three former
employees of Optex (who are now employed by Bausch & Lomb). The payments were
made on May 11, 2001, and represented the settlement of claims made by the
employees subsequent to the asset purchase agreement referred to above for
severance monies allegedly due under their employment agreement. Atlantic did
9
not believe these monies were due pursuant to the terms of the transaction
itself and the respective employment agreements. The board of directors elected
to acquiesce to the demands of the former employees and resolve the matter in
light of the potential future royalties from Bausch & Lomb and the importance of
these individuals to the ongoing development activities. The payment was
recorded as an expense netted against the gain on sale of Optex assets in the
September 30, 2001 consolidated statement of operations.
(11) PRIVATE PLACEMENT OF COMMON SHARES
On May 7, 2001, Atlantic entered into a common stock purchase
agreement with Fusion Capital Fund II, LLC, pursuant to which Fusion Capital
agreed to purchase up to $6.0 million of Atlantic's common stock over a 30-month
period, subject to a six-month extension or earlier termination at Atlantic's
discretion. This agreement replaced an earlier common stock purchase agreement
between Atlantic and Fusion Capital dated March 16, 2001. Fusion's obligation to
purchase Atlantic shares is subject to certain conditions, including the
effectiveness of a registration statement covering the shares to be purchased.
That registration statement was declared effective on July 6, 2001. The selling
price of the shares will be equal to the lesser of (1) $20.00 or (2) a price
based upon the future market price of the common stock, without any fixed
discount to the market price. A material contingency that may affect Atlantic's
operating plans and ability to raise funds under this agreement is its stock
price. Currently, Atlantic's stock price is below the floor price of $0.68
specified in the Fusion Capital agreement and as a result Atlantic is currently
unable to draw funds pursuant to the Fusion Capital agreement. As the Fusion
Capital agreement is currently structured, Atlantic cannot guarantee that it
will be able to draw any funds. To date, Atlantic has not drawn funds pursuant
to this agreement. Atlantic paid a finder's fee of $120,000 in connection with
signing this agreement and subsequently was required to issue 600,000 commitment
shares to Fusion Capital; those shares had an estimated fair value of $444,000.
General and administrative expense for the nine-month period ended September 30,
2001, include amounts relating to the finder's fee and issuance of stock in the
aggregate amount of $564,000.
On August 1, 2001, Atlantic agreed to issue 35,000 shares of its
common stock to each of BH Capital Investments, L.P. and Excalibur Limited
Partnership in return for their commitment to provide Atlantic with $3.5 million
of financing in connection with an asset purchase for which Atlantic had
submitted a bid. Atlantic subsequently issued those shares, but Atlantic did not
ultimately purchase those assets. Those shares had an estimated fair value of
$44,100, which is included as a general and administrative expense for the
three-and nine-month periods ended September 30, 2001.
(12) SALE OF GEMINI ASSETS
Pursuant to an asset purchase agreement dated April 23, 2001, among
Atlantic, Atlantic's majority-owned subsidiary Gemini Technologies, Inc., the
Cleveland Clinic Foundation ("CCF") and CCF's affiliate IFN, Inc., Gemini sold
to IFN substantially all its assets, including all those related to the 2-5A
antisense enhancing technology, for future contingent royalty payments and
withdrawal of CCF's arbitration demand against Atlantic and Gemini. The
transaction closed on May 5, 2001. This transaction was beneficial to Atlantic
since it permitted Atlantic to avoid terminating the Cleveland sublicense with
no compensation to Gemini and spared Atlantic from having to pay the substantial
shutdown costs that Gemini would likely have incurred without this asset
purchase agreement. In connection with this sale, Atlantic recorded a loss of
$334,408. This loss results from net assets sold to IFN of $136,408 and a
liability related to SBIR grant funds for research on the 2-5A antisense
technology, of approximately $198,000. Of the $198,000 accrual established upon
closing, $194,500 remains accrued at September 30, 2001.
(13) SUBSEQUENT EVENTS
In October 2001, Atlantic stopped work on CryoComm, a wholly-owned
subsidiary of Atlantic that had been developing superconducting electronics for
Internet packet switching and transport products. Discontinuing work on CryoComm
will allow Atlantic to focus on its core life-sciences technologies, although
Atlantic will continue to prosecute the patents on this technology. As part of
this restructuring, Walter Glomb's position was eliminated effective October 16,
2001, although Mr. Glomb will receive a 7% success fee if he is able to secure
funding to further develop this technology. As stated in his employment
agreement, Mr. Glomb will also receive a total of $62,500 in severance payments
due under his employment agreement over six months following his termination.
Such amounts will be recorded in the fourth quarter of 2001.
10
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations
---------------------------------------------
You should read the following discussion of our results of
operations and financial condition in conjunction with our Annual Report on Form
10-KSB/A for the year ended December 31, 2000. This discussion includes
"forward-looking" statements that reflect our current views with respect to
future events and financial performance. We use words such as we "expect,"
"anticipate," "believe," and "intend" and similar expressions to identify
forward-looking statements. Investors should be aware that actual results may
differ materially from our expressed expectations because of risks and
uncertainties inherent in future events, particularly those risks identified in
the "Risk Factors" section of our most recent Annual Report on Form 10-KSB/A,
and should not unduly rely on these forward looking statements.
RESULTS OF OPERATIONS
THREE-MONTH PERIOD ENDED SEPTEMBER 30, 2001 VS. 2000
In accordance with a license and development agreement, as amended,
Bausch & Lomb Surgical has paid our subsidiary, Optex Ophthalmologics, Inc.
("Optex"), for developing its Catarex technology. With the termination of this
agreement at the conclusion of the sale of substantially all of Optex's assets
(mostly intangible assets with no book value) in March 2001, as described
further below, we no longer have the revenues or profits associated with that
agreement available to us. As a result, for the three months ended September 30,
2001, this agreement provided no development revenue, and no related cost of
development revenue. For the three months ended September 30, 2000, this
agreement provided $1,072,716 of development revenue, and related cost of
development revenue of $858,173.
For the quarter ended September 30, 2001, research and development
expense was $172,257 as compared to $424,829 in the third quarter of 2000. This
decrease is primarily due to the cessation of research and development
activities on the antisense technology as a result of the sale of the assets of
Gemini.
Through September 30, 2000, we made an investment in TeraComm, Inc.
of $1,000,000 in cash and common stock and warrants valued at $1.8 million.
During the quarter ended September 30, 2000, we expensed $263,359 ($2,653,382
has been expensed through September 30, 2000) of this payment as acquired
in-process research and development since TeraComm's product development
activity was in its very early stages. As a result of TeraComm's not meeting a
technical milestone at December 31, 2000, no further investments were made in
TeraComm.
For the quarter ended September 30, 2001, general and administrative
expense was $496,294 as compared to $477,949 in the quarter ended September 30,
2000. This increase is principally due to an increase in payroll expenses of
approximately $38,000 and an increase in expenses associated with the issuance
of 35,000 shares of our common stock to each of BH Capital Investments, L.P. and
Excalibur Limited Partnership in August 2001 in return for their commitment to
provide us with $3.5 million of financing in connection with an asset purchase
for which we had submitted a bid. We subsequently issued those shares, but we
did not ultimately purchase those assets. Those shares had an estimated fair
value of $44,100, which was recorded as a general and administrative expense for
the three months ended September 30, 2001. These expense increases are offset by
a reduction in legal expenses of approximately $33,000, a reduction in travel
and entertainment expenses of about $17,000 and a reduction in other expenses of
$14,000 as a result of our efforts to reduce costs.
For the quarter ended September 30, 2001, we had compensation
expense relating to stock warrants of $35,968 as compared to $11,857 in the
prior year. The current quarter expense consists of $45,355 associated with
fully-vested warrants issued to Proteus Capital Corp. in August 2001 as partial
compensation for fundraising services, offset by a reduction in expense of
$9,387 associated with warrants issued to Dian Griesel as partial compensation
for investor-relations services. The reduction of compensation expense
associated with the warrants issued to Dian Griesel is a result of a decrease in
our stock price during the quarter. Additional expense associated with these
warrants will continue to be incurred over the remainder of the two-year term of
the agreement. As long as these warrants continue to vest, that expense will be
directly affected by the movement in the price of our common stock. For the
quarter ended September 30, 2000, the expense was associated with warrants
issued to
11
Joseph Stevens & Company as partial compensation for investment banking
services. Compensation expense relating to these investor relations and
investment banking services represent a general and administrative expense.
For the third quarter of 2001, interest and other income was $6,266,
compared to $22,940 in the third quarter of 2000. The decrease in interest
income is primarily due to the decline in our cash reserves.
Net loss applicable to common shares for the quarter ended September
30, 2001, was $735,562 as compared to $972,426 for the quarter ended September
30, 2000. This decrease in net loss applicable to common shares is attributable
to the recording of acquired in-process research and development expense in
conjunction with our investment in TeraComm Research, Inc. of $263,359 in the
third quarter of 2000, as well as a reduction of research and development
expenses of $252,572 from the quarter ended September 30, 2000, as compared to
2001. The net loss continues to include our share of TeraComm's losses. This
will cease when our investment in TeraComm of $8,351 included in our
consolidated balance sheet at September 30, 2001, is reduced to zero. The loss
differential is partially reduced by the termination of our agreement with
Bausch & Lomb. Since we no longer have the revenue or profits associated with
that agreement available to us, we had no profit resulting from this agreement
in the third quarter of 2001 as compared with $214,543 in the third quarter of
2000.
NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2001 VS. 2000
In accordance with a license and development agreement, as amended,
Bausch & Lomb Surgical has paid our subsidiary, Optex Ophthalmologics, Inc.
("Optex"), for developing its Catarex technology. For the nine months ended
September 30, 2001, this agreement provided $2,461,922 of development revenue
and related cost of development revenue of $2,082,568. For the nine months ended
September 30, 2000, this agreement provided $3,419,831 of development revenue
and related cost of development revenue of $2,735,865. The decrease in revenues
and related expenses over last year was due to the fact that there were no
revenues and related expenses since the termination of the agreement in March
2001. The decrease is offset by the recognition of a project completion bonus of
$1,067,345 paid out and recognized at the completion of the project in March
2001. With the termination of the above agreement at the conclusion of the sale
of substantially all of Optex's assets (mostly intangible assets with no book
value) in March 2001, as described further below, we will no longer have the
revenues or profits associated with that agreement available to us.
For the nine months ended September 30, 2001, research and
development expense was $774,340 as compared to $854,927 for the nine months
ended September 30, 2000. This decrease is due mainly to the cessation of
research and development activities on the antisense technology as a result of
the sale of the assets of Gemini. This decrease is offset somewhat by increased
expenditures on certain development projects, including CT-3 during the first
part of the year.
Through September 30, 2000, we made an investment in TeraComm, Inc.
of $1,000,000 in cash and common stock and warrants valued at $1.8 million. For
the nine months ended September 30, 2000, we expensed $2,653,382 of this payment
as acquired in-process research and development since TeraComm's product
development activity was in its very early stages. As a result of TeraComm's not
meeting a technical milestone at December 31, 2000, no further investments were
made in TeraComm.
For the nine months ended September 30, 2001, general and
administrative expense was $2,333,567 as compared to $1,595,463 for the nine
months ended September 30, 2000. This increase is largely due to an increase in
payroll costs over last year of approximately $130,000, and an increase in
expenses incurred in conjunction with a common stock purchase agreement entered
into during the second quarter of 2001 with Fusion Capital Fund II, LLC. These
expenses include the cost of our issuing 600,000 commitment shares to Fusion
Capital of $444,000 and a finders fee of $120,000. Fusion's obligation to
purchase our shares is subject to certain conditions, including the
effectiveness of a registration statement covering the shares to be purchased.
That registration statement was declared effective on July 6, 2001. A material
contingency that may affect our operating plans and ability to raise funds under
this agreement is our stock price. Currently, our stock price is below the floor
price of $0.68 specified in the Fusion Capital agreement and as a result we are
currently unable to draw funds pursuant to the Fusion Capital agreement. As the
Fusion Capital agreement is currently structured, we cannot guarantee that we
will be able to draw any funds. To date, we have not drawn funds pursuant to
this agreement. See "Liquidity and Capital Resources" for further details on
this agreement. In addition, we incurred expenses associated with the issuance
of 35,000 shares of our common stock to each of BH Capital Investments, L.P. and
Excalibur Limited Partnership in
12
August 2001 in return for their commitment to provide us with $3.5 million of
financing in connection with an asset purchase for which we had submitted a bid.
We did not ultimately purchase those assets. Those shares had an estimated fair
value of $44,100 which was recorded as a general and administrative expense for
the nine months ended September 30, 2001.
For the nine months ended September 30, 2001, we had compensation
expense relating to stock warrants of $70,634 as compared to $1,073,511 in the
prior year. The current year expense consists of $25,279 associated with
warrants issued to Dian Griesel during March 2001 as partial compensation for
investor relations services and $45,355 associated with fully vested warrants
issued to Proteus Capital Corp in August 2001 as partial compensation for fund
raising services. Additional expense associated with the warrants issued to Dian
Griesel will continue to be incurred over the remainder of the two-year term of
the agreement. As long as these warrants continue to vest, that expense will be
directly affected by the movement in the price of our common stock. For the nine
months ended September 30, 2000, we had $1,073,511 of expense associated with
warrants issued to Joseph Stevens & Company as partial compensation for
investment banking services. Compensation expense relating to these investor
relations and investment banking services represent a general and administrative
expense.
For the nine months ended September 30, 2001, interest and other
income was $40,618, compared to $97,267 in the nine months ended September 30,
2000. The decrease in interest income is primarily due to the decline in our
cash reserves.
Net loss applicable to common shares for the nine months ended
September 30, 2001, was $2,044,369 as compared to $6,249,540 for the nine months
ended September 30, 2000. This decrease in net loss applicable to common shares
is attributable in part to a gain on the sale of the assets of our subsidiary,
Optex, recognized during the nine months ended September 30, 2001 in the amount
of $2,569,451, partially offset by a distribution to the minority shareholders
of Optex of $837,274 (see further discussion of this sale below). In addition,
the decrease in net loss applicable to common shares is compounded by the
recording of acquired in-process research and development expense in conjunction
with our investment in TeraComm, Inc. of $2,653,382 in the nine months ended
September 30, 2000. In the nine months ended September 30, 2000, we recorded
compensation expense of $1,073,511 relating to stock warrants issued to Joseph
Stevens & Company compared with compensation expense of $70,634 relating to
stock warrants issued to the Dian Griesel and Proteus Capital Corp. during the
current year. The loss differential is partially reduced by a loss recorded on
the sale of the assets of Gemini of $334,408 in the nine months ended September
30, 2001 and the cost of our issuing 600,000 commitment shares to Fusion Capital
Fund II, LLC of $444,000 incurred in the nine months ended September 30, 2001.
In addition, with the termination of our agreement with Bausch & Lomb, we no
longer have the revenue or profits associated with that agreement available to
us. As a result, we had a reduction in profit from this agreement of $304,612
from the nine months ended September 30, 2000 as compared to 2001.
Net loss applicable to common shares for the nine months ended
September 30, 2001 also included a beneficial conversion on shares of our Series
B preferred stock in the amount of $600,000 and a dividend of $167,127 paid upon
the repurchase of the outstanding shares of Series B preferred stock recorded
during the nine months ended September 30, 2001. We also issued preferred stock
dividends on our Series A preferred stock for which the estimated fair value of
$107,449 and $811,514 was included in the net loss applicable to common shares
for the nine months ended September 30, 2001 and 2000, respectively. The
decrease in the estimated fair value of these dividends as compared to the prior
year is primarily a reflection of the decline in our stock price and a reduction
of the number of preferred shares issued.
LIQUIDITY AND CAPITAL RESOURCES
From inception to September 30, 2001, we incurred an accumulated
deficit of $26,163,254, and we expect to continue to incur additional losses
through the year ending December 31, 2001 and for the foreseeable future. The
loss has been incurred through primarily research and development activities
related to the various technologies under our control.
Pursuant to an asset purchase agreement dated January 31, 2001,
among Bausch & Lomb, a Bausch & Lomb affiliate, Atlantic, and Optex, on March 2,
2001, Optex sold to Bausch & Lomb substantially all its assets (mostly
intangible assets with no book value), including all those related to the
Catarex technology. As a result of this sale, Atlantic and Optex no longer have
any obligations to Bausch & Lomb in connection with development of
13
the Catarex technology. The purchase price was $3 million paid at closing
(approximately $564,000 of which was distributed to the minority shareholders).
In addition, Optex is entitled to receive additional consideration, namely $1
million once Bausch & Lomb receives regulatory approval to market the Catarex
device in Japan, royalties on net sales on the terms stated in the original
development agreement dated May 14, 1998, between Bausch & Lomb and Optex, as
amended, and minimum royalties of $90,000, $350,000, and $750,000 for the first,
second, and third years, respectively, starting on first commercial use of the
Catarex device or January 1, 2004, whichever is earlier. Optex also has the
option to repurchase the acquired assets from Bausch & Lomb if it ceases
developing the Catarex technology at fair value. Upon the sale of Optex assets,
Bausch & Lomb's development agreement with Optex was terminated. In the asset
purchase agreement Optex agreed to forgo future contingent payments provided for
in the earlier development agreement. As a result of this transaction, we
recorded a gain on the sale of Optex assets of $2,569,451. We made a profit
distribution of $837,274 to Optex's minority shareholders, representing their
share of the cumulative profit from the development agreement with Bausch & Lomb
and the proceeds from the sale of Optex' assets.
On September 28, 2000, pursuant to a convertible preferred stock and
warrants purchase agreement (the "Purchase Agreement"), we issued to BH Capital
Investments, L.P. and Excalibur Limited Partnership (together, the "Investors")
for a purchase price of $2,000,000, 689,656 shares of our Series B convertible
preferred stock and warrants to purchase 134,000 shares of our common stock.
Half of the shares of Series B preferred stock (344,828 shares) and warrants to
purchase half of the shares of common stock (67,000 shares) were held in escrow,
along with half of the purchase price.
On December 4, 2000, Atlantic and the Investors entered into a stock
repurchase agreement (the stock "Repurchase Agreement") pursuant to which we
repurchased from the Investors for $500,000 137,930 shares of Series B preferred
stock, and agreed to the release from escrow to the Investors of the $1,000,000
purchase price of the 344,828 shares of Series B preferred stock held in escrow.
We also allowed the Investors to keep all of the warrants issued under the
purchase agreement and issued to the Investors warrants to purchase a further
20,000 shares of our common stock at the same exercise price. On January 19,
2001, 41,380 shares of Series B preferred stock were converted by the Investors
into 236,422 shares of our common stock. On March 9, 2001, Atlantic and the
Investors entered into a second stock repurchase agreement pursuant to which we
repurchased from the Investors, for an aggregate purchase price of $617,067, all
165,518 shares of our Series B preferred stock held by the Investors. The
repurchase price represented 125% of the purchase price originally paid by the
investors for the repurchased shares, as well as an amount equal to the annual
dividend on the Series B preferred stock at a rate per share of 8% of the
original purchase price. The repurchased shares constitute all remaining
outstanding shares of Series B preferred stock; we have cancelled those shares.
On May 7, 2001, we entered into a common stock purchase agreement
with Fusion Capital Fund II, LLC pursuant to which Fusion Capital agreed to
purchase up to $6.0 million of our common stock over a 30-month period, subject
to a 6-month extension or earlier termination at our discretion. This agreement
replaced an earlier common stock purchase agreement between Atlantic and Fusion
Capital dated March 16, 2001. Fusion's obligation to purchase shares of our
common stock is subject to certain conditions, including the effectiveness of a
registration statement covering the shares to be purchased. That registration
statement was declared effective on July 6, 2001. The selling price of the
shares will be equal to the lesser of (1) $20.00 or (2) a price based upon the
future market price of the common stock, without any fixed discount to the
market price. A material contingency that may affect our operating plans and
ability to raise funds under this agreement is our stock price. Currently, our
stock price is below the floor price of $0.68 specified in the Fusion Capital
agreement and as a result we are currently unable to draw funds pursuant to the
Fusion Capital agreement. As the Fusion Capital agreement is currently
structured, we cannot guarantee that we will be able to draw any funds. To date,
we have not drawn funds pursuant to this agreement. We paid a $120,000 finder's
fee relating to this transaction to Gardner Resources, Ltd. and issued to Fusion
Capital Fund II, LLC 600,000 common shares as a commitment fee. Those shares had
an estimated fair value of $444,000. We have amended our agreement with Fusion
Capital to allow Atlantic to draw funds pursuant to the agreement regardless of
its listing status on the Nasdaq SmallCap Market.
On November 6, 2001, we entered into an agreement with Joseph
Stevens & Company, Inc. in which Joseph Stevens agreed to act as placement agent
for a private placement of shares of our common stock. In that private
placement, the price of each share of our common stock will be $0.24 and the
minimum and maximum subscription amounts will be $2,000,000 and $3,000,000,
respectively. In addition, each investor will receive a warrant to purchase one
share of our common stock for every share of our common stock purchased by that
investor.
14
The warrants will have an exercise price of $0.29 and will be exercisable for
five years from the closing date. In connection with the offering, we will pay
to Joseph Stevens a placement fee equal to 7% of the aggregate subscription
amount plus 10% of the number of shares and warrants issued to the investors.
Joseph Stevens has informed us that as of the end of November 19, 2001,
investors had placed in escrow over $1,000,000 towards the aggregate
subscription price of this private placement, and we expect that by November 30,
2001, we will have received commitments for at least the minimum aggregate
subscription amount and will be able to close this financing. There can,
however, be no assurances that the closing will take place by then, or at all.
Our available working capital and capital requirements will depend
upon numerous factors, including progress of our research and development
programs; our progress in and the cost of ongoing and planned preclinical and
clinical testing; the timing and cost of obtaining regulatory approvals; the
cost of filing, prosecuting, defending, and enforcing patent claims and other
intellectual property rights; competing technological and market developments;
changes in our existing collaborative and licensing relationships; the resources
that we devote to developing manufacturing and commercializing capabilities;
technological advances; the status of our competitors; our ability to establish
collaborative arrangements with other organizations; and our need to purchase
additional capital equipment.
At September 30, 2001, we had $440,558 in cash and cash equivalents.
As of September 30, 2001, our current liabilities exceeded our current assets
and we had a working capital deficit of $280,607. We anticipate that our
resources, before any proceeds from the proposed private placement, will be
sufficient to finance our anticipated needs for operating and capital
expenditures at our current level of operations for at least the next several
weeks. We anticipate, however, that the proceeds we expect to receive from the
private placement conducted through Joseph Steven & Company, Inc. would be
sufficient to finance our anticipated needs for operating and capital
expenditures at our current level of operations for at least the next year. In
addition, we will attempt to generate capital through a combination of
collaborative agreements, strategic alliances, and debt financing. However, we
can give no assurance that we will be able to obtain additional capital through
these sources or upon terms acceptable to us.
We have the following short term and long term liquidity needs. Our
cash utilized for operations for the next year is expected to be approximately
$150,000 per month. Currently, these expected operating expenses include
approximately $40,000 per month for research and preclinical development
expenses and approximately $110,000 for general and administrative expenses.
Based on our cash position of $440,558 at September 30, 2001, we will have to
raise additional funds within the next month to fund our current spending
requirements. At present, we have reduced or eliminated planned levels of
development activities.
On August 9, 2001, we retained Proteus Capital Corp. on a
non-exclusive basis as our investment bankers to assist us with raising
additional funds. Pursuant to our agreement with Proteus, we granted Proteus
warrants to purchase 100,000 shares of our common stock at $0.59 per share,
which was the average closing stock price for the two weeks ending August 17,
2001. The warrants were fully vested on the date of the agreement and the term
of the warrants is five years.
Subsequent to an oral hearing before a Nasdaq Listing Qualifications
Panel, on August 23, 2001, our securities were delisted from the Nasdaq Stock
Market for failing to meet the minimum bid price requirements set forth in the
NASD Marketplace Rules, as our common stock had traded for less than $1.00 for
more than 30 consecutive business days. Our common stock trades now on the OTC
Bulletin Board under the symbol "ATLC.OB". Delisting our common stock from
Nasdaq could have a material adverse effect on our ability to raise additional
capital, our stockholders' liquidity and the price of our common stock.
RESEARCH AND DEVELOPMENT ACTIVITIES
Optex and the Catarex(TM) Technology
Our majority-owned (81.2%) subsidiary, Optex, is entitled to
royalties and other revenues in connection with commercialization of the Catarex
technology. Bausch & Lomb, a multinational ophthalmics company, is developing
this technology to overcome the limitations and deficiencies of traditional
cataract extraction techniques. Optex had been the owner of this technology and
was developing it pursuant to a development agreement with Bausch & Lomb, but on
March 2, 2001, Optex sold to Bausch & Lomb substantially all of its assets
(mostly
15
intangible assets with no book value), including those related to the Catarex
technology, and delivered 2,400 "First-Generation" Catarex handpieces to Bausch
& Lomb for use in Human Feasibility Studies and Clinical Trials.
Bausch & Lomb, which has committed over $15 million on the project
to date, has assumed full responsibility for development and marketing of the
technology, and will pay Optex royalties on sales of the device and associated
system.
Bausch & Lomb planned to conduct a Human Feasibility Study on the
First Generation Catarex handpiece at a location outside the United States in
mid- September 2001, but cancelled it due to several factors including the
immediate concern surrounding extended travel as a result the September 11, 2001
terrorist tragedy.
Accordingly, Bausch & Lomb informed us that, in an effort to
accelerate the project, it will combine the Feasibility Study and Clinical
Trials on the First-Generation Catarex handpiece into one study under an FDA
approved Investigational Device Exemption (IDE). Bausch & Lomb considers that
the risk of combining the two studies is minimal since all the studies to date
indicate that the system operates as intended.
Bausch & Lomb informed us that it plans to submit the IDE to the FDA
in the fourth quarter of 2001. Once received, the FDA requires 30 days for
review and approval. This would allow Bausch & Lomb to begin the trials as early
as the first quarter of 2002, depending on the speed of patient registration.
Once the Clinical Trails are completed there will be a 90 day follow-up period,
and then the data will be submitted in a report to the FDA along with a 510(k)
application for the First-Generation Catarex handpiece.
Bausch & Lomb has also informed us that it is continuing to develop
the Second-Generation Catarex handpiece that better integrates the "back-end"
plumbing of the Catarex handpiece with its Millenium Surgical platform, but
retains unchanged the "front-end" surgical instrument of the Catarex handpiece
that enters the human eye during surgery. Since the front-end of the
Second-Generation handpiece is unchanged from the First-Generation handpiece,
Bausch & Lomb believes that FDA 510(k)/IDE approval of the First-Generation
Catarex handpiece should streamline FDA approval of the Second-Generation
Catarex handpiece by allowing it to be filed under a straight 510(k) application
scheduled to follow shortly thereafter.
CT-3 Anti-inflammatory/Analgesic Compound
We are developing our proprietary compound CT-3, a patented
synthetic derivative of carboxylic tetrahydrocannabinol (THC-7C), as an
alternative to nonsteroidal anti-inflammatory drugs, or "NSAIDs," such as
aspirin and ibuprofen. Over 130 million Americans suffer from chronic pain and
40 million suffer from arthritis. Worldwide prescription sales of
analgesic/anti-inflammatory drugs exceeded $9 billion in 1999. Preliminary
studies have shown that CT-3 demonstrates analgesic/anti-inflammatory properties
at microgram doses without central nervous system or gastrointestinal side
effects and also reduces joint damage caused by rheumatoid arthritis.
Since CT-3 appears to possess a wide range of therapeutic activity,
we are carefully choosing an indication that we feel CT-3 would be most
efficacious for and one that will strategically allow us to increase the
licensing value of CT-3 in the most timely and cost effective manner. We are
continuing our efforts by conducting additional preclinical tests to study the
analgesic activity of CT-3, particularly with reference to neuropathic pain.
Preliminary results show that CT-3 intraperitoneally dramatically reduces
allodynia in neuropathic rats (with a partial sciatic nerve ligation). We are
planning to initiate shortly a Phase I/II clinical trial of safety,
tolerability, and efficacy to determine the upper limits of safe dosing with
CT-3 and to measure the potential for CT-3 to act as a pain reliever in patients
with neuropathic pain. In addition, we have recently initiated a development
plan for CT-3 to test its efficacy in multiple sclerosis. In an animal model for
multiple sclerosis, CT-3 induced a significant decrease in spasticity,
demonstrated a rapid inhibition of limb stiffness and the effect was relatively
long-lived. The results of the study validated spasticity as a potential
indication for CT-3 use. We are also preparing to conduct Phase II clinical
trials to evaluate the efficacy of CT-3 in multiple sclerosis-associated tremors
and spasticity.
We are continuing to develop CT-3 for use in the treatment of a
variety of indications. In order to significantly increase the potential value
of a sublicensing deal, we have determined to delay sublicensing CT-3, to
suitable strategic partners to assist in clinical development, regulatory
approval filing, manufacturing and marketing of CT-3 until after successful
completion of the Phase II Clinical Trials.
16
CryoComm
In October 2001, we stopped work on CryoComm, a wholly-owned
subsidiary of Atlantic that had been developing superconducting electronics for
Internet packet switching and transport products. CryoComm had developed and
identified all the elements required to demonstrate an ultrafast fiber-optic
packet switch based in superconducting electronics and had been seeking directed
investment of $5 million to fund this demonstration. We have presented this plan
to major global long-haul telecommunications carriers, and although their
responses have been uniformly positive, and although they have encouraged us to
proceed with this development, we have not be able to secure a directed
investment from them or from other private funding sources. Moreover, we
determined that we would be unlikely to secure financing for the foreseeable
future, given the recent dramatic slowdown in planned telecommunication
infrastructure spending, a slowdown that is partially the result of current
overcapacity and an especially harsh economic downward correction in the
telecommunications equipment sector.
Discontinuing work on CryoComm will allow us to focus on our core
life-sciences technologies, although we will continue to prosecute the patents
on this technology. As part of this restructuring, Walter Glomb's position was
eliminated effective October 16, 2001, although Mr. Glomb will receive a 7%
success fee if he is able to secure funding to further develop this technology.
He will also receive a total of $62,500 in severance payments due under his
employment agreement over six months following his termination.
RECENT DEVELOPMENTS
On November 6, 2001, we entered into an agreement with Joseph
Stevens & Company, Inc. in which Joseph Stevens agreed to act as placement agent
for a private placement of shares of our common stock. In that private
placement, the price of each share of our common stock will be $0.24 and the
minimum and maximum subscription amounts will be $2,000,000 and $3,000,000,
respectively. In addition, each investor will receive a warrant to purchase one
share of our common stock for every share of our common stock purchased by that
investor. The warrants will have an exercise price of $0.29 and will be
exercisable for five years from the closing date. In connection with the
offering, we will pay to Joseph Stevens a placement fee equal to 7% of the
aggregate subscription amount plus 10% of the number of shares and warrants
issued to the investors.
We anticipate that proceeds from this private placement will be
sufficient to finance our anticipated needs for operating and capital
expenditures at our current level of operations for at least the next year. We
expect that by November 30, 2001, we will have received commitments for the
minimum aggregate subscription amount and will be able to close this financing.
17
PART II -- OTHER INFORMATION
Item 2. Changes in Securities
(c) Recent Sales of Unregistered Securities
Shares of common stock issued to BH Capital Investments, L.P.
and Excalibur Limited Partnership
On August 1, 2001, we agreed to issue 35,000 shares of our common
stock to each of BH Capital Investments, L.P. and Excalibur Limited Partnership
in return for their commitment to provide us with $3.5 million of financing in
connection with an asset purchase for which we had submitted a bid. We
subsequently issued those shares but ultimately did not purchase those assets.
In issuing these shares, we relied on the exemption from registration provided
by Regulation D of the Securities Act.
Warrants issued to Proteus Capital Corp. for the purchase
of shares of common stock.
On August 9, 2001, we entered into an agreement with Proteus Capital Corp
("Proteus") in which Proteus agreed to assist us with raising additional funds.
Pursuant to this agreement, we granted Proteus warrants to purchase 100,000
shares of our common stock at $0.59 per share, which was the average closing
stock price for the two weeks ending August 17, 2001. The warrants were fully
vested on the date of the agreement and were outstanding at September 30, 2001.
The term of the warrants is five years. In issuing these shares, we relied on
the exemption from registration provided by Regulation D of the Securities Act.
Item 4. Submission of Matters to a Vote of Security Holders
On July 17, 2001, we filed with the Securities and Exchange
Commission a definitive proxy statement seeking stockholder approval of the
following three proposals at the annual meeting of stockholders held on August
8, 2001:
1. RESOLVED, that Frederic P. Zotos, Steve H. Kanzer, Peter O. Kliem
and A. Joseph Rudick be and hereby are re-elected as directors of Atlantic, to
serve until their respective successors are duly elected and qualified.
2. RESOLVED, that the board of directors' selection of KPMG LLP to
serve as Atlantic's independent auditors for the year ending December 31, 2001,
hereby is ratified.
3. RESOLVED, that Atlantic may transact such other business as may
be properly come before the Annual Meeting and any adjournment or adjournments
thereof.
All three proposals were approved by our stockholders. Having
received more than 98% of the 6,187,435 votes cast, Dr. Rudick, Mr. Zotos, Mr.
Kanzer and Mr. Kliem were duly elected. The appointment of KPMG as our auditor
was approved by 6,177,595 votes (or 99.8%) of the 6,187,435 votes cast. The
resolution authorizing us to transact such other business as may properly come
before the annual meeting and any adjournments thereof was approved by 6,022,611
(or 97.3%) of the 6,187,435 votes cast.
Item 5. Other Information
Delisting of Our Securities
As of March 20, 2001, the minimum bid price of our common stock had
been less than $1.00 for 30 consecutive business days. This constituted a
failure on our part to meet Nasdaq's continued inclusion requirement for minimum
bid price.
On March 22, 2001, Nasdaq notified us of this failure, and we had a
period of 90 calendar days from that notice to comply with the continued
inclusion standard for minimum bid price. To do so, we would have had to meet
that standard for a minimum of 10 consecutive business days during the 90-day
compliance period. We failed
18
to do so, and on June 21, 2001, Nasdaq notified us that we would be delisted on
June 29, 2001, unless by June 28, 2001, we requested a hearing before Nasdaq's
Listing Qualifications Panel.
On June 28, 2001, we requested a hearing, and that hearing was held
on August 9, 2001. On August 23, 2001, our securities were delisted from the
Nasdaq Stock Market for failing to meet the minimum bid price requirements set
forth in the NASD Marketplace Rules. Our common stock now trades on the OTC
Bulletin Board under the symbol "ATLC.OB". Delisting of our common stock from
Nasdaq could have a material adverse effect on our ability to raise additional
capital, our stockholders' liquidity and the price of our common stock.
Item 6: Exhibits and Reports on Form 8-K
Exhibits
The following documents are referenced or included in this report.
Exhibit No. Description
----------- -----------
3.1(1) Certificate of incorporation of Atlantic, as amended to date.
3.2(1) Bylaws of Atlantic, as amended to date.
3.3(5) Certificate of designations of Series A Convertible Preferred
Stock.
3.4(6) Certificate of increase of Series A Convertible Preferred Stock.
3.5(9) Certificate of designations, preferences and rights of Series B
convertible preferred stock of Atlantic, filed on September 28,
2000.
3. 6(9) Certificate of amendment of the certificate of
designations, preferences and rights of Series B convertible
preferred stock of Atlantic, filed on November 17, 2000.
3.7(10) Certificate of amendment of the certificate of designations,
preferences and rights of Series B convertible preferred stock
of Atlantic, filed on January 9, 2001.
3.8(10) Certificate of amendment of the certificate of designations,
preferences and rights of Series B convertible preferred stock
of Atlantic, filed on January 19, 2001.
4.2(1) Form of unit certificate.
4.3(1) Specimen common stock certificate.
4.4(1) Form of redeemable warrant certificate.
4.5(1) Form of redeemable warrant agreement by and between Atlantic and
Continental Stock Transfer & Trust Company.
4.6(1) Form of underwriter's warrant certificate.
4.7(1) Form of underwriter's warrant agreement by and between Atlantic
and Joseph Stevens & Company, L.P.
4.8(1) Form of subscription agreement by and between Atlantic and the
Selling Stockholders.
4.9(1) Form of bridge note.
4.10(1) Form of bridge warrant.
19
4.11(2) Investors' rights agreement by and among Atlantic, Dreyfus
Growth and Value Funds, Inc. and Premier Strategic Growth Fund.
4.12(2) Common stock purchase agreement by and among Atlantic, Dreyfus
Growth and Value Funds, Inc. and Premier Strategic Growth Fund.
10.2(1) Employment agreement dated July 7, 1995, between Atlantic and
Jon D. Lindjord.
10.3(1) Employment agreement dated September 21, 1995, between Atlantic
and Dr. Stephen R. Miller.
10.4(1) Employment agreement dated September 21, 1995, between Atlantic
and Margaret A. Schalk.
10.5(1) Letter agreement dated August 31, 1995, between Atlantic and Dr.
H. Lawrence Shaw.
10.6(1) Consulting agreement dated January 1, 1994, between Atlantic and
John K. A. Prendergast.
10.8(1) Investors' Rights agreement dated July 1995, between Atlantic,
Dr. Lindsay A. Rosenwald and VentureTek, L.P.
10.9(1) License and assignment agreement dated March 25, 1994, between
Optex Ophthalmologics, Inc., certain inventors and NeoMedix
Corporation, as amended.
10.10(1) License agreement dated May 5, 1994, between Gemini Gene
Therapies, Inc. and the Cleveland Clinic Foundation.
10.11(1)+ License agreement dated June 16, 1994, between Channel
Therapeutics, Inc., the University of Pennsylvania and certain
inventors, as amended.
10.12(1)+ License agreement dated March 28, 1994, between Channel
Therapeutics, Inc. and Dr. Sumner Burstein.
10.13(1) Form of financial advisory and consulting agreement by and
between Atlantic and Joseph Stevens & Company, L.P.
10.14(1) Employment agreement dated November 3, 1995, between Atlantic
and Shimshon Mizrachi.
10.15(3) Financial advisory agreement between Atlantic and Paramount
dated September 4, 1996 (effective date of April 15, 1996).
10.16(3) Financial agreement between Atlantic, Paramount and UI USA dated
June 23, 1996.
10.17(3) Consultancy agreement between Atlantic and Dr. Yuichi Iwaki
dated July 31, 1996.
10.18(3) 1995 stock option plan, as amended.
10.19(3) Warrant issued to an employee of Paramount Capital, LLC to
purchase 25,000 shares of Common Stock of Atlantic.
10.20(3) Warrant issued to an employee of Paramount Capital, LLC to
purchase 25,000 shares of Common Stock of Atlantic.
10.21(3) Warrant issued to an employee of Paramount Capital, LLC to
purchase 12,500 shares of Common Stock of Atlantic.
10.22(4) Letter agreement between Atlantic and Paramount Capital, Inc.
dated February 26,1997.
20
10.23(4) agreement and plan of reorganization by and among Atlantic,
Channel Therapeutics, Inc. and New Channel, Inc. dated February
20, 1997.
10.24(4) Warrant issued to John Prendergast to purchase 37,500 shares of
Atlantic's Common Stock.
10.25(4) Warrant issued to Dian Griesel to purchase 24,000 shares of
Atlantic's Common Stock.
10.26(7) Amendment No. 1 to development & license agreement by and
between Optex and Bausch & Lomb Surgical, Inc. dated September
16, 1999.
10.27(8) Financial advisory and consulting agreement by and between
Atlantic and Joseph Stevens & Company, Inc. dated January 4,
2000.
10.28(8) Warrant No. 1 issued to Joseph Stevens & Company, Inc. to
purchase 150,000 shares of Atlantic's Common Stock exercisable
January 4, 2000.
10.29(8) Warrant No. 2 issued to Joseph Stevens & Company, Inc. to
purchase 150,000 shares of Atlantic's Common Stock exercisable
January 4, 2001.
10.30(8) Warrant No. 3 issued to Joseph Stevens & Company, Inc. to
purchase 150,000 shares of Atlantic's Common Stock exercisable
January 4, 2002.
10.31(9) Preferred stock purchase agreement dated May 12, 2000, between
Atlantic and TeraComm Research, Inc.
10.32(9) Warrant certificate issued May 12, 2000, by Atlantic to TeraComm
Research, Inc.
10.33(9) Stockholders agreement dated May 12, 2000, among TeraComm
Research, Inc., the common stockholders of TeraComm, and
Atlantic.
10.34(9) Registration rights agreement dated May 12, 2000, between
Atlantic and TeraComm Research, Inc. with respect to shares of
TeraComm preferred stock issued to Atlantic.
10.35(9) Registration rights agreement dated May 12, 2000, between
Atlantic and TeraComm Research, Inc. with respect to shares of
Atlantic common stock issued to TeraComm.
10.36(9) Employment agreement dated as of April 10, 2000, between
Atlantic and A. Joseph Rudick.
10.37(9) Employment agreement dated as of April 3, 2000, between Atlantic
and Frederic P. Zotos.
10.38(9) Employment agreement dated as of April 10, 2000, between
Atlantic and Nicholas J. Rossettos, as amended.
10.39(9) Employment agreement dated as of May 15, 2000, between Atlantic
and Walter Glomb.
10.40(9) Employment agreement dated as of April 18, 2000, between
Atlantic and Kelly Harris.
10.41(10) Amendment dated as of July 18, 2000, to the Preferred Stock
Purchase agreement dated May 12, 2000, between Atlantic and
TeraComm Research, Inc.
10.42(10) Convertible preferred stock and warrants purchase agreement
dated September 28, 2000, among Atlantic, BH Capital
Investments, L.P. and Excalibur Limited Partnership.
10.43(10) Registration rights agreement dated September 28, 2000, among
Atlantic, BH Capital Investments, L.P., and Excalibur Limited
Partnership.
21
10.44(10) Escrow agreement dated September 28, 2000, among Atlantic, BH
Capital Investments, L.P., and Excalibur Limited Partnership.
10.45(10) Form of stock purchase warrants issued on September 28, 2000, to
BH Capital Investments, L.P., exercisable for shares of common
stock of Atlantic.
10.46(10) Form of stock purchase warrants issued on September 28, 2000, to
Excalibur Limited Partnership, exercisable for shares of common
stock of Atlantic.
10.47(10) Amendment No. 1 dated October 31, 2000, to convertible preferred
stock and warrants purchase agreement dated September 28, 2000,
among Atlantic, BH Capital Investments, L.P., and Excalibur
Limited Partnership.
10.48(12) Stock repurchase agreement dated December 4, 2000, among
Atlantic, BH Capital Investments, L.P., and Excalibur Limited
Partnership.
10.49(14) Letter agreement dated December 28, 2000, among Atlantic and BH
Capital Investments, L.P., and Excalibur Limited Partnership.
10.50(11) Amendment No. 2 dated January 9, 2001, to convertible preferred
stock and warrants purchase agreement dated September 28, 2000,
among Atlantic, BH Capital Investments, L.P., and Excalibur
Limited Partnership.
10.51(14) Amendment No. 1 dated January 9, 2001, to registration rights
agreement dated September 28, 2000, among Atlantic and BH
Capital Investments, L.P. and Excalibur Limited Partnership.
10.52(11) Amendment No. 3 dated January 19, 2001, to convertible preferred
stock and warrants purchase agreement dated September 28, 2000,
among Atlantic, BH Capital Investments, L.P., and Excalibur
Limited Partnership.
10.53(14) Letter agreement dated January 25, 2001, among Atlantic and BH
Capital Investments, L.P., and Excalibur Limited Partnership.
10.54(13) Stock repurchase agreement No. 2 dated March 9, 2001, among
Atlantic, BH Capital Investments, L.P., and Excalibur Limited
Partnership.
10.55(15) Common stock purchase agreement dated March 16, 2001, between
Atlantic and Fusion Capital Fund II, LLC.
10.56(15) Warrant certificate issued March 8, 2001 by Atlantic to Dian
Griesel.
10.57(16) Common stock purchase agreement dated as of May 7, 2001, between
Atlantic and Fusion Capital Fund II, LLC.
10.58(16) Form of registration rights agreement between Atlantic and
Fusion Capital Fund II, LLC.
10.59* Asset purchase agreement dated as of January 31, 2001, between
Bausch & Lomb Incorporated, Bausch & Lomb Surgical, Inc., Optex
Ophthalmologics, Inc. and Atlantic (the "January 31 Asset
Purchase Agreement).
10.60* Amendment No. 1 dated March 2, 2001, to the January 31 Asset
Purchase Agreement.
10.61* Asset purchase agreement dated as of April 23, 2001, between
Atlantic, Gemini Technologies, Inc., and IFN, Inc.
21.1(1) Subsidiaries of Atlantic.
22
------
+ Confidential treatment has been granted as to certain portions
of these exhibits.
* Filed herewith.
(1) Incorporated by reference to exhibits of Atlantic's registration
statement on Form SB-2, Registration #33-98478, as filed with
the Securities and Exchange Commission (the "SEC") on October
24, 1995 and as amended by Amendment No. 1, Amendment No. 2,
Amendment No.3, Amendment No. 4 and Amendment No. 5, as filed
with the SEC on November 9, 1995, December 5, 1995, December 12,
1995, December 13, 1995 and December 14, 1995, respectively.
(2) Incorporated by reference to exhibits of Atlantic's Current
Report on Form 8-K, as filed with the SEC on August 30, 1996.
(3) Incorporated by reference to exhibits of Atlantic's Form 10-QSB
for the period ended September 30, 1996.
(4) Incorporated by reference to exhibits of Atlantic's Form 10-QSB
for the period ended March 31, 1996.
(5) Incorporated by reference to exhibits of Atlantic's Current
Report on Form 8-KSB, as filed with the SEC on June 9, 1997.
(6) Incorporated by reference to exhibits of Atlantic's Registration
Statement on Form S-3 (Registration No. 333-34379), as filed
with the Commission on August 26, 1997, and as amended by
Amendment No. 1 as filed with the SEC on August 28, 1997.
(7) Incorporated by reference to exhibits of Atlantic Form 10-QSB
for the period ended September 30, 1999.
(8) Incorporated by reference to exhibits of Atlantic's Form 10-KSB
for the period ended December 31, 1999.
(9) Incorporated by reference to exhibits of Atlantic's Form 10-QSB
for the period ended June 30, 2000.
(10) Incorporated by reference to exhibits of Atlantic's Form 10-QSB
for the period ended September 30, 2000.
(11) Incorporated by reference to exhibits of Atlantic's Form 8-K
filed on January 24, 2001.
(12) Incorporated by reference to exhibits of Atlantic's Form 8-K
filed on December 11, 2000.
(13) Incorporated by reference to exhibits of Atlantic's Form 8-K
filed on March 14, 2001.
(14) Incorporated by reference to exhibits of Atlantic's Form 10-KSB
filed on April 17, 2001.
(15) Incorporated by reference to exhibits of Atlantic's Form 10-QSB
for the period ended March 31, 2001.
(6) Incorporated by reference to exhibits of Atlantic's Registration
Statement on Form SB-2 (Registration No. 333-61974), as filed
with the Commission on May 31, 2001, and as amended by Amendment
No. 1 as filed with the SEC on June 29, 2001.
23
Reports on Form 8-K
No reports on Form 8-K were filed during the quarter for which this
report is filed.
24
SIGNATURES
In accordance with the requirements of the Exchange Act, Atlantic
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
ATLANTIC TECHNOLOGY VENTURES, INC.
Date: November 19, 2001 /s/ Fredric P. Zotos
-----------------------------------
Frederic P. Zotos
President, Chief Executive Officer,
and Director
Date: November 19, 2001 /s/ Nicholas J. Rossettos
-----------------------------------
Nicholas J. Rossettos
Chief Financial Officer